Colleran David 4
4 · Anika Therapeutics, Inc. · Filed Mar 19, 2024
Insider Transaction Report
Form 4
Colleran David
EVP, General Counsel, Corp Sec
Transactions
- Award
Restricted Stock Unit
2024-03-15+19,345→ 19,345 totalExercise: $0.00→ Common Stock (19,345 underlying) - Award
Stock Option (Right to Buy)
2024-03-15+46,875→ 46,875 totalExercise: $27.98Exp: 2034-03-11→ Common Stock (46,875 underlying)
Footnotes (3)
- [F1]Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025.
- [F2]Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
- [F3]The premium priced stock options vest in three equal annual installments beginning on March 15, 2025.